Diagnostic and Prognostic Value of PACAP in Multiple Myeloma.

Int J Mol Sci · 2023 · PMC10341744 · PMID 37445974

Europe PMC DOI

hedged sentences

0.0833

closest p · 1.7× alpha

0.1547

boldest claim

The sentences

a negative trendp = 0.0833so close (0.05 < p ≤ 0.1)

Besides, we found a negative trend for PACAP-38 and erythrocyte sedimentation rate (ESR) ( n = 25, p = 0.0833, r = −0.3531), urinary total protein (UTP) ( n = 23, p = 0.0522, r = −0.4191) and serum kappa/lambda ratio (KLR) above 1.65 ( n = 18, p = 0.1144, r = −0.3849), but there was a positive trend with KLR below 0.26 ( n = 8, p = 0.1323, r = 0.5952).

also in 1,426 other papers

a positive trendp = 0.1323not close (p > 0.1)

Besides, we found a negative trend for PACAP-38 and erythrocyte sedimentation rate (ESR) ( n = 25, p = 0.0833, r = −0.3531), urinary total protein (UTP) ( n = 23, p = 0.0522, r = −0.4191) and serum kappa/lambda ratio (KLR) above 1.65 ( n = 18, p = 0.1144, r = −0.3849), but there was a positive trend with KLR below 0.26 ( n = 8, p = 0.1323, r = 0.5952).

also in 3,891 other papers

a decreasing trendp = 0.1547not close (p > 0.1)

For the R-ISS and cytogenetic risk scores, we found no significant difference between the tested groups ( p > 0.05), but there was a decreasing trend between Stages I and II ( p = 0.1547) ( Table 3 ).

also in 20,123 other papers

an increasing trendno p-value reported

A similarly promising and effective agent is daratumumab, which also showed an increasing trend in PACAP, but presumably due to the small number of elements, no significant difference was detected.

also in 25,319 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.